Ravidasvir - Presidio Pharmaceuticals

Drug Profile

Ravidasvir - Presidio Pharmaceuticals

Alternative Names: ASC-16; BI-238630; C5; PPI-668

Latest Information Update: 10 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator XTL Biopharmaceuticals
  • Developer Ascletis; Drugs for Neglected Diseases Initiative Foundation; Ministry of Public Health (Thailand); Pharco Corporation; Presidio Pharmaceuticals
  • Class Antivirals; Benzimidazoles; Carbamates; Naphthalenes; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS 5 protein inhibitors; Hepatitis C virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preregistration Hepatitis C

Most Recent Events

  • 06 Aug 2018 Efficacy data from a phase II/III trial in Hepatitis C released by Ascletis Pharma
  • 31 Jul 2018 Preregistration for Hepatitis C (Combination therapy, Treatment-naive) in China (PO)
  • 12 Jun 2018 Ascletis announces intention to submit NDA for HCV infection in third quarter of 2018
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top